Data Sheet | June 4, 2026
Tumor Protein Mapping Platform
Get the Resource
Services Request - Tumor Proteomics
Submit your request for a Tumor Proteomics study using the form below.
"*" indicates required fields
As ADCs, T-cell engagers, radioligand therapies, and immunotherapies have reached technical maturity, success in modern oncology drug development is no longer limited by the availability of therapeutic modalities but rather increasingly depends on accurate tumor proteome characterization across multiple functional dimensions – including druggable surface targets, signaling pathway activation, immune engagement, and mechanisms of resistance.
Sapient’s Tumor Protein Mapping Platform directly measures the functional tumor proteome by integrating complementary mass spectrometry workflows into a single platform that enables end-to-end measurement of tumor biology at scale across the proteome.
In combination, these workflows create a closed-loop system that captures tumor biology across 12,000+ protein groups, providing a unified, system-level understanding of tumor biology to guide oncology drug development from target selection through clinical proof of concept.
How the Platform Enables Comprehensive Tumor Proteome Characterization
The Sapient Tumor Protein Mapping Platform generates and integrates direct protein measurements that inform critical decisions across oncology programs. All workflows are performed using the same analytical framework, allowing direct comparison across biological dimensions within a study.
| Sapient Workflow | Biological Dimension | Depth and Insight |
|---|---|---|
| DiscoverySeek™ | Global protein expression, including protein isoforms | Comprehensive measure of over 12,000 proteins across tissues |
| SurfaceSeek™ | Cell surface protein expression | Surface protein density and druggable target accessibility for ADC, T-cell engager, and radioligand therapies |
| SignalingSeek™ | Phosphorylation-driven pathway activity | Functional pathway activation, mechanism of action, and adaptive response |
| ImmuneSeek™ | Immune cell composition and activation states | Tumor immune microenvironment characterization |
| ResistanceSeek™ | Resistance-associated protein networks | Resistance pathway activity and therapeutic vulnerability |
| Targeted Protein Assays | Quantitative measurement of specific proteins of interest | Target quantitation, drug distribution, MOA, target engagement, and pharmacodynamics |
This transforms tumor profiling from a collection of disconnected assays into a coherent biological system of record. Each workflow informs the others, enabling teams to build a complete picture of the tumor proteome within a single experimental framework.
From Genomic Inference to Direct Protein Measurement
Historically, drug development has relied on incomplete and indirect measurements of tumor biology. By directly measuring proteins – the molecules that define cellular function – Sapient provides an integrated and actionable view of tumor biology across discovery, translational research, and clinical development. Our Tumor Protein Mapping Platform shifts oncology R&D from:
- Fragmented datasets to a unified biological system
- Indirect proxy measures via genomics to direct protein-level measurements
- Biological inference to direct measure of functional biology and targets
- Preclinical assumptions to measurement in human tumors
Download the white sheet to explore how Sapient’s Tumor Protein Mapping Platform enables mechanism-driven development strategies grounded in comprehensive tumor proteome characterization – because programs that integrate functional evidence earlier in development reduce the risk of late-stage failure.
What development questions can the Tumor Protein Mapping Platform help answer?
Our Tumor Protein Mapping workflows can be delivered singularly or in the combination that best informs your studies, addressing:
| Development Question | Platform Insight |
|---|---|
| What defines tumor biology or drug mechanism of action in this indication? | DiscoverySeek proteome-wide mapping |
| Which cell surface targets are accessible and druggable? | SurfaceSeek direct surface proteomics |
| What signaling pathways are functionally active? | SignalingSeek phosphoproteomics |
| How is the immune system engaged? | ImmuneSeek immune cell and checkpoint profiling |
| Why are patients failing therapy? | ResistanceSeek resistance pathway measurement |
| Is the therapeutic working as intended? | Quantitative target engagement assay |
In addition to proteomics, Sapient enables integrated multi-omics analysis in FFPE tumor samples, including with DNA sequencing, single-cell sequencing, and spatial profiling. This allows comprehensive characterization of tumor biology within the same tissue context. Integrated capabilities include:
Enable Direct, Multi-Dimensional Tumor Proteome Characterization – Get Started Today
Sapient’s Tumor Protein Mapping workflows can be leveraged as standalone methods or flexibly combined to best answer your distinct development questions. The platform is available through flexible engagement models including project-based proteomics services, data licensing, and integrated discovery partnerships.
Use the form to request a meeting or email discover@sapient.bio to set up a time to talk about your study needs.
Get the Resource
Services Request - Tumor Proteomics
Submit your request for a Tumor Proteomics study using the form below.
"*" indicates required fields